Pathway Based Analysis of Mutation Data Is Efficient for Scoring Target Cancer Drugs

Despite the significant achievements in chemotherapy, cancer remains one of the leading causes of death. Target therapy revolutionized this field, but efficiencies of target drugs show dramatic variation among individual patients. Personalization of target therapies remains, therefore, a challenge i...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Marianna A. Zolotovskaia, Maxim I. Sorokin, Anna A. Emelianova, Nikolay M. Borisov, Denis V. Kuzmin, Pieter Borger, Andrew V. Garazha, Anton A. Buzdin
Format: Artigo
Sprache:Inglês
Veröffentlicht: Frontiers Media S.A. 2019-01-01
Schriftenreihe:Frontiers in Pharmacology
Schlagworte:
cancer
DNA mutation
molecular pathways
biomarker
target drugs
tyrosine kinase inhibitors
Online Zugang:https://www.frontiersin.org/article/10.3389/fphar.2019.00001/full
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge